Real-world data at ARVO highlight transformational outcomes seen with Lucentis®, including lower injection frequency than in original clinical trials
8 May 2013 | By Novartis
"Lucentis was designed to save sight..."
List view / Grid view
8 May 2013 | By Novartis
"Lucentis was designed to save sight..."
7 May 2013 | By B&W Tek
B&W Tek is pleased to announce the completion of its first series of educational videos...
7 May 2013 | By kdm communications limited
Scientists at the specialised biotech company PharmAbcine are completing formulation and stability studies in a fraction of the time...
7 May 2013 | By Amgen
Study meets primary endpoint of non-inferiority in monotherapy setting...
6 May 2013 | By Novo Nordisk
Novo Nordisk is investing an additional 380 million Danish kroner in its Kalundborg plant in Denmark...
6 May 2013 | By Bristol-Myers Squibb Company
ARISTOTLE studied Eliquis vs. warfarin...
6 May 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC)...
3 May 2013 | By Merck
LIPTRUZET approved for patients with primary or mixed hyperlipidemia, as an adjunct to diet when diet alone is not enough...
3 May 2013 | By GlaxoSmithKline
GlaxoSmithKline announced a funding injection of up to £5m from the Wellcome Trust...
3 May 2013 | By kdm communications limited
The new system will help the DKMS accelerate...
3 May 2013 | By Bristol-Myers Squibb Company
The U.S. FDA has approved a sNDA for SUSTIVA® (efavirenz)...
2 May 2013 | By Sanofi
A new commercial organization to better align with its business priorities...
2 May 2013 | By Gilead Sciences
Gilead Sciences announced plans to initiate a third Phase 3 clinical trial...
1 May 2013 | By kdm communications limited
The Buccaneer range of advanced waterproof power and data connectors has been independently rated to IP69K – DIN 40050-9
1 May 2013 | By Merck
Merck's board of directors has authorized additional purchases of up to $15 billion of Merck’s common stock for its treasury.